Go to content Go to menu
 


INO 4800

2020-04-09
INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, which causes the COVID-19 disease in humans. Inovio's proprietary platform hand-held smart device called CELLECTRA® is leading the way forward for activation immunotherapy. This one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual's immune system to generate a robust targeted T cell and antibody response. CELLECTRA uses a brief electrical pulse to open small pores in the cell reversibly to allow the plasmids to enter. Once inside the cell, the plasmids begin replicating, thereby strengthening the body's own natural response mechanisms. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. Inovio is aiming to significantly expand the therapeutic range of monoclonal antibodies with its DNA-encoded monoclonal antibody technology. With dMAb, Inovio encodes DNA to express a monoclonal antibody. Injection of the DNA plasmid into a patient generates robust in vivo monoclonal antibody production. This approach has the potential to generate in vivo production of therapeutic antibodies. Inovio's DNA medicines are not interfering with or changing in any way an individual's own DNA. INO-4800 is a DNA vaccine candidate designed to prevent novel coronavirus SARS-CoV-2 from infecting humans, which causes COVID-19 disease. Another Inovio vaccine candidate, INO-4700, targets MERS-CoV, a related coronavirus. To date, preclinical results of this vaccine candidate were well tolerated and induced high levels of antibody responses in 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 used in that trial were maintained through 60 weeks following dosing.